New dQ&A Study:
Exclusive Insights on 3,000+ Patients
Over 5 Years
What's the Story?
Our latest Diabetes Drug Insights study follows a group of more than n=3,000 people with type 2 diabetes in the USA from 2018 to 2024.
The study tracks this cohort (sourced from members of the dQ&A USA Patient Panel) to understand not only the changes in their therapy regimens, including GLP-1s, SGLT-2s, CGM, and insulin use, but also the resulting impact on their clinical outcomes, such as A1c levels and BMI.
What’s New?
Diabetes Drug Insights covers many topics, including; GLP-1 likelihood to recommend, a closer look at GLP-1 ‘Early Quitters,’ and what PCPs are doing to help deal with GLP-1 side effects.
Diabetes Drug Insights: Selected Data
GLP-1 NPS by Brand
Currently, 69% of T2 GLP-1 users in the dQ&A USA Patient Panel are using one of the two leading GLP-1 brands on the market.
One of these brands has maintained a consistent net promoter score (NPS) over the past two years and, more recently, has widened the gap relative to the competition.
- Among T2s that quit using a top GLP-1 over the past 2 years, 32% did so within the first 3 months and nearly half did so within the first 6 months.
- However, quitting one brand doesn’t necessarily mean they’re lost to the class forever; just over 50% of T2s that quit a GLP-1 switched to a different brand within the class.
- Reasons for quitting are often driven by the brand they started on; quitters for one leading brand most often cite access/supply issues as a reason for quitting, while quitters for another leading brand more often cite side effects (most notably nausea).
How PCPs Help Manage Side Effects
Primary care physicians (PCPs) play a vital role in prescribing GLP-1s and managing patients who use them.
Half or more of PCPs that are prescribing GLP-1s also provide diet recommendations and/or prescribe anti-emetics to assist patients in handling potential side effects.
Karen
Creative, Up-beat Moderator/Interviewer
"Insights I draw from our amazing panelists influence our client's smart decisions and directly improve life for very people I get to interview! How great is that?!”
Trevor
Mixed-Methods Research Expert. Multiple Published Papers.
"As someone with T1D, I'm grateful our work directly impacts devices and therapies”
Christianne
Data Services Architect. Career Research Guru.
“I have been working with dQ&A for over ten years, 100% focused on diabetes. I so love contributing to those mission-critical decisions.”
Phin
VP, Research Services. Structures big data to drive analysis and insight.
“It's a real privilege to work with data that can make such a significant difference”
Kim
10 Years on the Client Side. Delivers Actionable Insights
“At dQ&A I’m surrounded by seasoned researchers and compassionate individuals, united in our mission to make life better for people living with diabetes”
Phyllisa
Patient Advocate. Manages Content for People With Diabetes
“For the first time in my career, I don't deal with diabetes stigma in the workplace.”
You have Questions. We have Answers.
Contact us to gain insight into the GLP-1 patient experience through our
latest findings in the Diabetes Drug Insights study.
Do you have questions on dQ&A Diabetes Drug Insights or other diabetes topics?
This research excerpt is just the tip of the iceberg. dQ&A has decades of experience across the United States, Canada, and Europe. If you drive critical diabetes research decisions in your organization, dQ&A is the diabetes insight partner that can get the answers you need.
